StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
13
Publishing Date
2024 - 03 - 04
14
2023 - 12 - 21
13
2023 - 12 - 12
13
2023 - 12 - 06
13
2023 - 10 - 18
12
2023 - 10 - 16
16
2023 - 10 - 04
14
2023 - 09 - 26
17
2023 - 09 - 20
12
2023 - 09 - 07
13
2023 - 08 - 23
12
2023 - 06 - 26
13
2023 - 04 - 25
15
2023 - 04 - 17
14
2023 - 02 - 23
13
2023 - 01 - 30
16
2023 - 01 - 25
13
2022 - 10 - 12
13
2022 - 08 - 22
13
2022 - 06 - 06
11
2022 - 05 - 24
11
2022 - 05 - 17
13
2022 - 05 - 03
12
2022 - 05 - 02
11
2022 - 03 - 28
14
2022 - 01 - 24
18
2022 - 01 - 20
11
2022 - 01 - 18
11
2021 - 12 - 22
12
2021 - 12 - 21
11
2021 - 12 - 13
15
2021 - 12 - 09
12
2021 - 12 - 06
13
2021 - 11 - 29
11
2021 - 11 - 12
11
2021 - 11 - 01
12
2021 - 10 - 25
11
2021 - 10 - 19
11
2021 - 10 - 18
15
2021 - 10 - 14
12
2021 - 10 - 12
12
2021 - 10 - 07
12
2021 - 10 - 04
12
2021 - 09 - 30
11
2021 - 09 - 09
11
2021 - 09 - 07
12
2021 - 08 - 24
11
2021 - 06 - 29
12
2021 - 06 - 28
11
2021 - 06 - 25
13
2021 - 06 - 23
14
2021 - 06 - 21
13
2021 - 06 - 11
11
2021 - 06 - 04
13
2021 - 06 - 03
12
2021 - 06 - 01
14
2021 - 05 - 21
15
2021 - 05 - 03
14
2021 - 04 - 14
11
2021 - 03 - 22
13
Sector
Health technology
13
Process industries
1
Tags
Acquisition
3
Application
2
Approval
6
Authorized
2
Battery
3
Biopharma
2
Biotech-beach
2
Biotechnology
2
Brands
4
Cancer
4
Cardio
2
Cell carcinoma
3
Ceo
4
Children
3
China
2
Chip
3
Chmp
8
Communication
2
Conference
11
Contract
3
Covid
4
Device
2
Diabetes
11
Disease
4
Drug
5
Efruxifermin
4
Electronics
3
Ema
2
Energy
7
Europe
9
Ev
4
Events
6
Eye
2
Fibrosis
2
Financial results
9
Food
2
Glass
2
Growth
5
Immunotherapy
2
Leo
3
License
3
Liver
6
Market
15
Media
3
Merge
3
N/a
239
Nash
3
Offering
17
People
3
Positive
10
Publication
8
Regulatory
4
Research
5
Restaurant
4
Results
22
T-cell
3
Technology
4
Therapy
5
Treatment
13
Trial
14
Entities
Abbott laboratories
1
Abbvie inc.
1
Akero therapeutics, inc.
1
Bausch health companies inc.
1
Biomarin pharmaceutical inc.
2
Bristol-myers squibb company
2
Codexis, inc.
1
Gilead sciences, inc.
1
Incyte corporation
2
Johnson & johnson
1
Morphosys ag
2
Novartis ag
1
Pfizer, inc.
1
Regeneron pharmaceuticals, inc.
2
Rubius therapeutics, inc.
1
Sanofi
2
Synlogic, inc.
1
Teleflex incorporated
1
Utah medical products, inc.
1
Xencor, inc.
2
Y-mabs therapeutics, inc.
1
Symbols
ABBV
1
ABT
1
AKRO
1
BHC
1
BMRN
2
BMY
2
CDXS
1
GILD
1
INCY
2
JNJ
1
MOR
2
NVS
1
PFE
1
REGN
2
RUBY
1
SNY
2
SYBX
1
TFX
1
UTMD
1
XNCR
2
YMAB
1
Exchanges
Nasdaq
10
Nyse
4
Crawled Date
2021 - 06 - 25
13
Crawled Time
06:00
2
07:00
2
12:00
2
12:15
1
13:00
1
13:15
1
15:00
1
16:00
1
17:00
1
18:00
1
Source
investors.biomarin.com
1
www.akerotx.com
1
www.biospace.com
3
www.globenewswire.com
3
www.prnewswire.com
5
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
publishing date :
2021 - 06 - 25
tags :
Treatment
save search
The Worldwide Cryptococcosis Treatment Industry is Expected to Reach $6 Billion by 2026 at a CAGR of 4.5% from 2021
Published:
2021-06-25
(Crawled : 18:00)
- prnewswire.com
PFE
A
|
$25.39
-0.12%
-0.12%
36M
|
Health Technology
|
-35.14%
|
O:
-0.18%
H:
0.73%
C:
-0.36%
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
0.67%
|
O:
0.16%
H:
0.09%
C:
-0.13%
JNJ
|
News
|
$145.74
0.67%
0.0%
9.3M
|
Health Technology
|
-11.28%
|
O:
-0.26%
H:
1.13%
C:
0.78%
BMY
|
$48.3
0.96%
-0.1%
11M
|
Health Technology
|
-26.65%
|
O:
0.12%
H:
1.76%
C:
1.23%
BHC
|
$8.6
-0.69%
0.0%
2.1M
|
Health Technology
|
-70.58%
|
O:
0.44%
H:
1.19%
C:
0.2%
ABT
|
News
|
$105.27
-0.6%
-0.15%
7.3M
|
Health Technology
|
-4.74%
|
O:
0.16%
H:
1.23%
C:
0.75%
treatment
Global Phenylketonuria Treatment Market (2021 to 2026) - by Type, Route, End-user and Geography
Published:
2021-06-25
(Crawled : 17:00)
- prnewswire.com
SYBX
|
$1.74
-1.7%
-1.72%
70K
|
Health Technology
|
-59.31%
|
O:
0.69%
H:
0.0%
C:
-4.11%
RUBY
|
$0.057
-99.3%
760K
|
Health Technology
|
-99.78%
|
O:
0.31%
H:
0.04%
C:
-3.02%
CDXS
|
News
|
$2.8
1.45%
1.43%
620K
|
Process Industries
|
-87.42%
|
O:
0.76%
H:
0.89%
C:
0.18%
BMRN
S
|
$90.08
-0.43%
-0.43%
940K
|
Health Technology
|
8.73%
|
O:
0.66%
H:
1.39%
C:
0.55%
treatment
phenylketonuria
Increased adiponectin following efruxifermin treatment is associatedwith improvements in dyslipidemia, glucose metabolism, and liver health in a 16-week, randomized, placebo-controlled trial in NASH
Published:
2021-06-25
(Crawled : 16:00)
- akerotx.com
AKRO
|
$20.535
-4.93%
-5.19%
760K
|
Health Technology
|
-27.88%
|
O:
0.11%
H:
0.35%
C:
-2.92%
treatment
nash
liver
efruxifermin
trial
Global Postpartum Hemorrhage (PPH) Treatment Devices Market to Reach $928.1 Million by 2026
Published:
2021-06-25
(Crawled : 15:00)
- prnewswire.com
TFX
|
News
|
$207.38
-0.44%
0.0%
150K
|
Health Technology
|
-48.2%
|
O:
0.48%
H:
4.27%
C:
2.35%
UTMD
|
$67.13
-0.73%
-0.73%
39K
|
Health Technology
|
-21.07%
|
O:
-0.69%
H:
3.43%
C:
2.26%
treatment
device
Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Receives Positive Opinion on Orphan Medicinal Product Designation by EMA
Published:
2021-06-25
(Crawled : 13:15)
- globenewswire.com
YMAB
|
$14.97
-0.93%
-0.94%
410K
|
Health Technology
|
-56.14%
|
O:
0.35%
H:
2.4%
C:
-0.69%
treatment
positive
ema
designation
MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Published:
2021-06-25
(Crawled : 13:00)
- biospace.com/
XNCR
|
$18.98
-0.47%
-0.47%
470K
|
Health Technology
|
-47.04%
|
O:
0.06%
H:
2.35%
C:
0.75%
MOR
|
$18.02
-0.11%
-0.11%
590K
|
Health Technology
|
-6.81%
|
O:
2.89%
H:
0.23%
C:
-0.55%
INCY
|
$52.82
0.19%
0.19%
1.8M
|
Health Technology
|
-38.67%
|
O:
-0.71%
H:
1.74%
C:
1.53%
treatment
positive
chmp
t-cell
Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Published:
2021-06-25
(Crawled : 12:15)
- biospace.com/
XNCR
|
$18.98
-0.47%
-0.47%
470K
|
Health Technology
|
-47.04%
|
O:
0.06%
H:
2.35%
C:
0.75%
MOR
|
$18.02
-0.11%
-0.11%
590K
|
Health Technology
|
-6.81%
|
O:
2.89%
H:
0.23%
C:
-0.55%
INCY
|
$52.82
0.19%
0.19%
1.8M
|
Health Technology
|
-38.67%
|
O:
-0.71%
H:
1.74%
C:
1.53%
treatment
positive
chmp
t-cell
BioMarin Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
Published:
2021-06-25
(Crawled : 12:00)
- investors.biomarin.com
BMRN
S
|
$90.08
-0.43%
-0.43%
940K
|
Health Technology
|
8.73%
|
O:
0.66%
H:
1.39%
C:
0.55%
treatment
europe
drop
positive
children
growth
chmp
achondroplasia
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
Published:
2021-06-25
(Crawled : 12:00)
- biospace.com/
BMY
|
$48.3
0.96%
-0.1%
11M
|
Health Technology
|
-26.65%
|
O:
0.12%
H:
1.76%
C:
1.23%
disease
treatment
positive
therapy
cancer
iot
chmp
nivolumab
CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis
Published:
2021-06-25
(Crawled : 07:00)
- prnewswire.com
ABBV
|
News
|
$164.66
0.25%
-0.15%
4.5M
|
Health Technology
|
43.94%
|
O:
-1.6%
H:
0.61%
C:
0.07%
treatment
dermatitis
approval
chmp
atopic dermatitis
Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
Published:
2021-06-25
(Crawled : 07:00)
- globenewswire.com
GILD
|
News
|
$66.16
-1.15%
-1.16%
6.4M
|
Health Technology
|
-0.42%
|
O:
-0.06%
H:
1.28%
C:
1.1%
covid
treatment
fda
children
merge
authorized
emergency use authorization
Libtayo® (cemiplimab) Approved by the European Commission for First-Line Treatment of Patients with Advanced Non-small Cell Lung Cancer with ≥50% PD-L1 Expression
Published:
2021-06-25
(Crawled : 06:00)
- prnewswire.com
SNY
|
News
|
$45.395
-1.55%
-1.58%
4.4M
|
Health Technology
|
-13.02%
|
O:
0.55%
H:
0.68%
C:
0.57%
REGN
|
$893.66
-0.84%
-0.84%
450K
|
Health Technology
|
65.52%
|
O:
-0.16%
H:
1.64%
C:
1.28%
treatment
lung cancer
europe
cancer
Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression
Published:
2021-06-25
(Crawled : 06:00)
- globenewswire.com
SNY
|
News
|
$45.395
-1.55%
-1.58%
4.4M
|
Health Technology
|
-13.02%
|
O:
0.55%
H:
0.68%
C:
0.57%
REGN
|
$893.66
-0.84%
-0.84%
450K
|
Health Technology
|
65.52%
|
O:
-0.16%
H:
1.64%
C:
1.28%
treatment
lung cancer
europe
cancer
Gainers vs Losers
64%
36%
Top 10 Gainers
AGBA
|
News
|
$1.02
155.0%
57.94%
120M
|
Finance
ZCMD
|
$2.86
108.76%
52.1%
2.3M
|
Commercial Services
INVO
|
$1.555
104.6%
51.13%
5M
|
Health Technology
ISPC
|
$0.437
105.16%
49.53%
37M
|
Professional, Scientific, and T...
WLGS
|
News
|
$0.92
84.0%
45.65%
1.6M
|
OST
|
$0.499
21.38%
45.26%
1.9M
|
XPON
|
News
|
$3.1
60.62%
37.74%
17M
|
TIRX
|
$0.7
44.39%
30.74%
58M
|
BNTC
|
News
|
$6.92
44.17%
30.64%
3.5M
|
Health Technology
GGE
|
$0.035
19.86%
29.3%
64M
|
Your saved searches
Save your searches and get alerts when important news are released.